2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses some of the exciting changes that have occurred in the field of multiple myeloma.
Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses some of the exciting changes that have occurred in the field of multiple myeloma.
There has been a large evolution in the management of these patients, he explains. Physicians have tried to change the treatment algorithms to achieve the best responses possible in all patient populations, including those who are elderly. This has helped with revised criteria.
With this, physicians will be able to begin doing early intervention with agents such as lenalidomide (Revlimid) and dexamethasone, as well as more aggressive induction consolidation and maintenance regimens.
Related Content: